





IDFC MULTI CAP FUND

(Previously known as IDFC Premier Equity Fund w.e.f. May 02, 2018) Multi Cap Fund - An open ended equity scheme investing across large cap, mid cap, small cap stocks.

FUND PHILOSOPHY

This is a multi-cap fund with equal weights in large, mid and small caps currently. The fund focuses on a benchmark agnostic investing style with a distinct underweight on financials and overweight on consumption and domestic cyclical in the current market conditions. At a stock level, the fund focuses on companies which are operating in segments where penetration of organized is still increasing and conversion to brands will be a key driver for long term growth. The fund favours companies which generate positive operating cash flow and consistently improve their Return on Capital Employed (RoCE). From time to time, the fund identifies stocks which are strong transformational targets both from operating parameters as well as corporate governance. The fund also aims to identify and capitalize on long term themes which could generate superior returns, even if they are present in the small cap segment.

FUND FEATURES:

Category: Multicap

Monthly Avg AUM: ₹5,484.73 Crores Inception Date: 28th September

2005

Fund Manager: Mr. Anoop Bhaskar (w.e.f. 30/04/2016) & Mr. Kartik Mehta (w.e.f. 02/04/2018)

Benchmark: S&P BSE 500 TRI

Minimum Investment Amount:

₹10,000/- and any amount thereafter. (Units of IDFC Multi Cap Fund, shall be available for lump sum subscription w.e.f. May 07, 2018)

Exit Load: 1.00% if redeemed before 365 days from the date of allotment. (w.e.f. 1st September, 2009)

SIP Frequency: Monthly (Investor may choose any day of the month except 29th, 30th and 31st as the date of instalment.)

Minimum SIP Investment Amount:

₹1000/- (w.e.f. 2nd May 2018)

Options Available: Growth, Dividend - (Payout, Reinvestment and Sweep (from Equity Schemes to Debt Schemes only))

Beta: 0.97 **R Square:** 0.86

Standard Deviation (Annualized):

14.36%

PLAN	DIVIDEND RECORD DATE	₹/UNIT	NAV
REGULAR	01-Mar-19	1.67	32.2300
	22-Mar-18	2.17	35.0577
	10-Mar-17	2.32	33.0348
DIRECT	01-Mar-19	1.74	33.5900
	22-Mar-18	2.25	36.2848
	10-Mar-17	2.38	33.9231

OUTLOOK

Headline CPI rose to 4.0% in September (vs. 3.2% last month) and came above consensus estimates (3.8%). The increase was primarily led by food prices which rose +1.3% MoM. Earnings have beaten expectations led by Autos and Financials with pre-tax profits up 13% YoY and 6% ahead of expectations. In sync with global markets, Indian equities also rallied with the NIFTY, NSE Midcap 100 and NSE Smallcap 100 rising 3.5%, 4.9% and 2.7% MoM respectively. Of the various factors needed for Cyclicals and Mid and Small Cap outperformance, we believe that quite a few are in favour namely – a good and above expected monsoon, government and RBI attention to turn around the flagging economy, favourable valuations, crude prices closer to USD 60, yields below 6.5% and a stable government at the centre.

Globally, sentiments could improve, if a comprehensive trade agreement between US-China, which could be perceived to reduce worries on the much forecasted US recession in 2020. US Real GDP growth at 1.9% QoQ in 3QCY19 came better-than-consensus estimates (1.6%). However, GDP growth has slowed down from previous quarters (3.0%/2.0% in 1QCY19/2QCY19). US-dollar broke below the 200-day moving average (down 2% MoM), despite Fed calling a halt to its rate cut cycle. UK pound (+5.3% MoM) and Euro (+2.3% MoM) rallied on reduced probability of a no-deal Brexit. Global equity markets rallied during the month with MSCI Emerging Markets (+4.1% MoM) outperforming MSCI Developed Markets (+2.5% MoM).

Face Value per Unit (in ₹) is 10


Dividend is not guaranteed and past performance may or may not be sustained in future. Pursuant to payment of dividend, the NAV of the scheme would fall to the extent of payout and statutory levy (as applicable).

	D	F	C
IDFC	мит	UAL	FUND

Name of the Instrument Ratings % t		Name of the Instrument Ratings	
Equity and Equity related Instruments	98.15%	AIA Engineering	1.13%
Banks	28.91%	Kirloskar Pneumatic Company	0.55%
ICICI Bank	8.38%	Commercial Services	4.05%
HDFC Bank	7.27%	3M India	4.05%
Axis Bank	5.95%	Retailing	3.40%
Kotak Mahindra Bank	4.01%	Avenue Supermarts	1.75%
City Union Bank	2.55%	Future Retail	1.28%
RBL Bank	0.74%	Future Lifestyle Fashions	0.37%
Consumer Non Durables	11.32%	Pharmaceuticals	2.78%
Asian Paints	3.66%	Sun Pharmaceutical Industries	1.42%
Britannia Industries	1.82%	Aurobindo Pharma	0.92%
Procter & Gamble Hygiene and Health Care	1.78%	Cadila Healthcare	0.45%
Nestle India	1.51%	Software	2.56%
Hindustan Unilever	1.16%	Infosys	2.56%
GlaxoSmithKline Consumer Healthcare	0.76%	Industrial Capital Goods	2.24%
S H Kelkar and Company	0.62%	Thermax	0.88%
Consumer Durables	11.29%	Disa India	0.73%
Bata India	3.32%	ABB India	0.63%
Voltas	3.24%	Cement	2.16%
Crompton Greaves Consumer Electricals	2.21%	UltraTech Cement	2.16%
Titan Company	1.80%	Auto Ancillaries	2.09%
Greenlam Industries	0.71%	Minda Industries	1.35%
Finance	7.55%	MRF	0.74%
HDFC Life Insurance Company	1.89%	IT Consulting & Other Services	1.86%
Multi Commodity Exchange of India	1.61%	Cognizant Technology Solutions	
ICICI Lombard General Insurance Company	1.32%	Corp - International Equities	1.86%
ICICI Securities	1.05%	Ferrous Metals	1.14%
JM Financial	0.92%	APL Apollo Tubes	1.14%
Mas Financial Services	0.77%	Transportation	1.12%
Construction Project	4.70%	Transport Corporation of India	1.12%
Larsen & Toubro	4.17%	Textiles - Cotton	0.98%
Power Mech Projects	0.53%	Vardhman Textiles	0.98%
Chemicals	4.66%	Media & Entertainment	0.47%
Atul	1.91%	Entertainment Network (India)	0.47%
Fine Organic Industries	1.38%	Pesticides	0.30%
Pidilite Industries	1.36%	Dhanuka Agritech	0.30%
Industrial Products	4.30%	Construction	0.28%
Schaeffler India	1.47%	Poddar Housing and Development	0.28%
Supreme Industries	1.17%	Net Cash and Cash Equivalent	1.85%
		Grand Total	100.00







This product is suitable for investors who are seeking*:

- To create wealth over long term
- Investment predominantly in equity and equity related instruments across market capitalisation.

*Investors should consult their financial advisors if in doubt about whether the product is suitable for them.

Distributed by:





